Knockout studies of liver-specific fatty acid synthase (FAS) have shown that PPAR-α agonists can reverse non-alcoholic steatohepatitis, indicating that FAS products act as PPAR-α activators [8]. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatohepatitis.